论文部分内容阅读
目的:观察宁泌泰联合坦索罗辛治疗慢性前列腺炎的临床疗效。方法:选择慢性前列腺炎120例,随机分为观察组和对照组各60例。观察组采用宁泌泰胶囊、坦索罗辛联合治疗,对照组单用坦索罗辛治疗;比较两组治疗前后的症状指数(NIH-CPSI)评分、前列腺液(EPS)白细胞计数及卵磷脂小体数量。结果:观察组总有效率91.7%,对照组总有效率78.3%,两组比较差异显著(P<0.05);两组均未出现明显不良反应。结论:宁泌泰联合坦索罗辛治疗慢性前列腺炎疗效优于单用坦索罗辛,且无明显不良反应。
Objective: To observe the clinical efficacy of Ningbitai combined with tamsulosin in the treatment of chronic prostatitis. Methods: 120 cases of chronic prostatitis were randomly divided into observation group and control group, 60 cases each. The observation group was treated with Ningbitai capsule and tamsulosin, while the control group was treated with tamsulosin alone. The NIH-CPSI score, leukocyte count of prostatic fluid (EPS) and lecithin Body number. Results: The total effective rate was 91.7% in the observation group and 78.3% in the control group, with significant difference between the two groups (P <0.05). No obvious adverse reactions were observed in both groups. Conclusion: Ningbitai combined with tamsulosin in the treatment of chronic prostatitis is better than tamsulosin alone, and no obvious adverse reactions.